SynthesisBMC cancer2025

Regulatory and clinical outcomes of priority-reviewed innovative cancer drugs in China between 2015 and 2024: an observational study.

Qi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.